H.I.G. Capital News

ForSight VISION5 Selected as a Red Herring Top 100 North America Winner

MENLO PARK, CA - June 8, 2015 - ForSight VISION5 today announced it was selected by Red Herring as one of the Top 100 North America award winners in recognition of its leadership in healthcare innovation. ForSight VISION5 is developing non-invasive drug delivery products to replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy.

"More than half of patients who are prescribed eye drops to manage their glaucoma do not refill their prescriptions after a year1 - often due to difficulty in using drops," said John Maroney, Chief Executive Officer of ForSight VISION5. "Our employees are dedicated to helping patients remain on their medications so they can manage their disease. We also continue to develop innovative products to serve other needs in ophthalmology."

Red Herring Top 100 America enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the U.S. and Canada. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, Palo Alto Networks and eBay would change the way we live and work.

Red Herring's editorial staff evaluated companies on both quantitative and qualitative criteria, such as financial performance, technological innovation and intellectual property, DNA of the founders, business model, customer footprint and addressable market.

"In 2015, selecting the top achievers was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across North America to the North America winners. We believe ForSight VISION5 embodies the vision, drive and innovation that define a successful entrepreneurial venture. ForSight VISION5 should be proud of its accomplishment, as the competition was very strong."

About ForSight VISION5, Inc.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5's lead product candidate is the Helios™ insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution. ForSight VISION5's investors include Versant Ventures, Morgenthaler Ventures, Technology Partners, Delphi Ventures, and H.I.G. BioVentures.

Company Contact Information:
Anne Brody Rubin
Vice President of Marketing
ForSight VISION5
Tel: (650) 325-2050 x119
information@forsightv5.com
www.forsightvision5.com

For Investors:
Lisa Wilson
President
In-Site Communications, Inc.
Tel: (917) 543-9932

1Nordstrom, BL et al. "Persistence and Adherence with Topical Glaucoma Therapy" Am J Ophthalmol 2005;140:598–606.